AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1474178 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg adinazolam mesylate sustained release tablet
Number of subjects: 36
Study 1474178 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg immediate release tablet
Number of subjects: 36
Study 1474178 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg intravenous adinazolam mesylate
Number of subjects: 36
Study 1474178 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly subjects
Number of subjects: 36
Study 1474178 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly volunteers
Number of subjects: 36
Study 1474178 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethyladinazolam
Number of subjects: 36
Study 6090280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g/day)
Number of subjects: 40
Study 6090280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg/day)
Number of subjects: 40
Study 6090280 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 40
Study 30862680 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF19 analog (NGM282)
Number of subjects: 0
Study 30862680 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery
Number of subjects: 0
Study 29894287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (180 mg before PCI)
Number of subjects: 40
Study 29894287 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (600 mg before PCI)
Number of subjects: 40
Study 29894287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 40
Study 29894287 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 40
Study 27688236 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 201
Study 27688236 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 201
Study 25157768 — intervention group
Group type: EXPERIMENTAL
Intervention: Motesanib 125 mg plus carboplatin/paclitaxel (Arm A)
Number of subjects: 360
Study 25157768 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus carboplatin/paclitaxel (Arm B)
Number of subjects: 360
Study 22527992 — intervention group
Group type: EXPERIMENTAL
Intervention: Social anxiety disorder patients
Number of subjects: 13
Study 22527992 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 13
Study 20102996 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 230
Study 20102996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil
Number of subjects: 230
Study 20102996 — intervention group
Group type: COMPARATOR
Intervention: Control group (individuals of similar gender and age without a clinical history of Lyme disease)
Number of subjects: 230
Study 18853833 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet gel (AG)
Number of subjects: 70
Study 18853833 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study 15837412 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body low-dose multidetector row-CT (MDCT)
Number of subjects: 100
Study 12505103 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (n = 18)
Number of subjects: 35
Study 12505103 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (n = 17)
Number of subjects: 35
Study 9888625 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 1 mg
Number of subjects: 10
Study 9888625 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 10
Study 9888625 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 10
Study 9888625 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 10
Study 9888625 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.75 mg
Number of subjects: 10
Study 9888625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8591350 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured abstracts
Number of subjects: 101
Study 8591350 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting
Number of subjects: 101
Study 2507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg p.o. plus metoprolol 50 mg p.o.
Number of subjects: 12
Study 2507667 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg p.o. plus i.m. scopolamine 0.006 mg/kg and morphine 0.2 mg/kg
Number of subjects: 12
Study 2507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Both combinations
Number of subjects: 12
Study 320090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol benzoat and hydroxyprogesterone capronat
Number of subjects: 265
Study 320090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no hormonal treatment)
Number of subjects: 265
Study 30638398 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (approximately 10^9 CFU) for 3 months
Number of subjects: 100
Study 30638398 — intervention group
Group type: COMPARATOR
Intervention: Calorie and protein-appropriate diet for 3 months (Control)
Number of subjects: 100
Study 27500908 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Family Systems (IFS) therapy
Number of subjects: 37
Study 27500908 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (CBT or IPT)
Number of subjects: 37
Study 25440273 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone at anesthesia induction (30 mg/kg IV)
Number of subjects: 45
Study 25440273 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone by CPB prime (30 mg/kg)
Number of subjects: 45
Study 25440273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 45
Study 23895807 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 232
Study 23895807 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 232
Study 23895807 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (MT)
Number of subjects: 232
Study 23895807 — intervention group
Group type: COMPARATOR
Intervention: Overall mortality (diabetics vs non-diabetics)
Number of subjects: 232
Study 23895807 — intervention group
Group type: COMPARATOR
Intervention: Cardiac mortality (diabetics vs non-diabetics)
Number of subjects: 232
Study 21112742 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoquinone (1mg/kg)
Number of subjects: 22
Study 21112742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release formulation of tramadol hydrochloride (TRH) based on osmotic technology
Number of subjects: 6
Study 19304555 — intervention group
Group type: COMPARATOR
Intervention: Commercial TRH tablets (control)
Number of subjects: 6
Study 19304555 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized formulation (batch IVB)
Number of subjects: 6
Study 17321948 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-session intervention
Number of subjects: 0
Study 17321948 — intervention group
Group type: COMPARATOR
Intervention: 1-session information session
Number of subjects: 0
Study 15351756 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine breastfeeding education plus peer counseling
Number of subjects: 165
Study 15351756 — intervention group
Group type: COMPARATOR
Intervention: Routine breastfeeding education
Number of subjects: 165
Study 11575344 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg ml(-1)
Number of subjects: 24
Study 11575344 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(-1)
Number of subjects: 24
Study 9394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 485
Study 9394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender interactions
Number of subjects: 485
Study 9394268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance and depressive symptoms relationship
Number of subjects: 485
Study 8099639 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 60
Study 3578927 — intervention group
Group type: COMPARATOR
Intervention: Anti-H1 antihistamines
Number of subjects: 80
Study 3578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cromolyn
Number of subjects: 80
Study 3578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 80
Study 3578927 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of H1 and H2 anti-histamine drugs
Number of subjects: 80
Study 30572273 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib
Number of subjects: 15828
Study 30572273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828
Study 29617585 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc slurry (4 g) administered through indwelling pleural catheter
Number of subjects: 154
Study 29617585 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered through indwelling pleural catheter
Number of subjects: 154
Study 26891133 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 500 (400 mg caffeine with 500 mL water)
Number of subjects: 66
Study 26891133 — intervention group
Group type: EXPERIMENTAL
Intervention: Water 1500 (1500 mL water)
Number of subjects: 66
Study 26891133 — intervention group
Group type: COMPARATOR
Intervention: Water 500 (500 mL water)
Number of subjects: 66
Study 26891133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study (caffeine intake evaluated via questionnaires)
Number of subjects: 66
Study 25128411 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise and home hazard reduction program
Number of subjects: 360
Study 22306436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium portion of M&M's in a small container (n=30)
Number of subjects: 88
Study 22306436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium portion of M&M's in a large container (n=29)
Number of subjects: 88
Study 22306436 — intervention group
Group type: EXPERIMENTAL
Intervention: Large portion of M&M's in a large container (n=29)
Number of subjects: 88
Study 21163119 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage (CE)
Number of subjects: 10
Study 21163119 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 21163119 — intervention group
Group type: COMPARATOR
Intervention: Tea
Number of subjects: 10
Study 17586130 — intervention group
Group type: EXPERIMENTAL
Intervention: N/EE35 (35 microg ethinyl estradiol)
Number of subjects: 60
Study 17586130 — intervention group
Group type: EXPERIMENTAL
Intervention: N/EE25 (25 microg ethinyl estradiol)
Number of subjects: 60
Study 15619391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 132
Study 15619391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 14665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (nine key presses with a temporal structure of eight intervals)
Number of subjects: 0
Study 14665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal (temporal structure of Combined but performed on one key)
Number of subjects: 0
Study 14665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinal (ordinal structure of Combined but an isochronous rhythm)
Number of subjects: 0
Study 14665684 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed temporal and random ordinal structure; random temporal and fixed ordinal structure; random temporal and ordinal structures
Number of subjects: 0
Study 10994884 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Enhancement Technologies active liquid cooling vest
Number of subjects: 26
Study 10994884 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Enhancement Technologies vest
Number of subjects: 26
Study 10994884 — intervention group
Group type: EXPERIMENTAL
Intervention: Steele vest
Number of subjects: 26
Study 10994884 — intervention group
Group type: COMPARATOR
Intervention: Passive cooling garments
Number of subjects: 26
Study 8631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-cyclodextrin drops (0.32% and 0.67%)
Number of subjects: 0
Study 8631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-cyclodextrin-polymer co-complexes
Number of subjects: 0
Study 8631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-cyclodextrin drops
Number of subjects: 0
Study 1563810 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin (400 mg b.i.d.)
Number of subjects: 49
Study 1563810 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 g t.i.d.)
Number of subjects: 49
Study 6151482 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837
Study 6151482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3837
Study 2979218 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms at bedtime
Number of subjects: 102
Study 2979218 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 102
Study 29858625 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble green/roasted coffee (6 g/day for 8 weeks)
Number of subjects: 52
Study 29858625 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (water or isotonic drink)
Number of subjects: 52
Study 28807576 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume of 10 mL kg−1 (G10)
Number of subjects: 36
Study 28807576 — intervention group
Group type: COMPARATOR
Intervention: Tidal volume of 12 mL kg−1 (G12)
Number of subjects: 36
Study 28807576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume of 15 mL kg−1 (G15)
Number of subjects: 36
Study 26044075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation (1000 mg calcium carbonate with 400 IU vitamin D daily)
Number of subjects: 34157
Study 26044075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34157
Study 26044075 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 34157
Study 23273601 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging individuals (20-99 years)
Number of subjects: 81
Study 23273601 — intervention group
Group type: EXPERIMENTAL
Intervention: Alzheimer's disease (AD)
Number of subjects: 81
Study 20974015 — intervention group
Group type: COMPARATOR
Intervention: Probiotic formulation (PF) consisting of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 administered for 30 days in humans
Number of subjects: 0
Study 20974015 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study 18504097 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural blockade (epidural nerve block with local anesthetic and/or opioids, neurolytic sympathetic plexus block, intrathecal nerve block with phenol)
Number of subjects: 136
Study 18504097 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural blockade
Number of subjects: 136
Study 16502746 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 18
Study 16502746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12773745 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 542
Study 12773745 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel monotherapy
Number of subjects: 542
Study 10840268 — intervention group
Group type: EXPERIMENTAL
Intervention: APPROACH group (intervention group)
Number of subjects: 2293
Study 10840268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2293
Study 9535619 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 12
Study 9535619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8265877 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10
Study 8265877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2949057 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sertraline
Number of subjects: 10
Study 2949057 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sertraline
Number of subjects: 10
Study 2949057 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sertraline
Number of subjects: 10
Study 2949057 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg zimelidine
Number of subjects: 10
Study 2949057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30037660 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of 25% albumin BID for three days
Number of subjects: 46
Study 30037660 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline placebo BID for three days
Number of subjects: 46
Study 27067532 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure CNI
Number of subjects: 282
Study 27067532 — intervention group
Group type: COMPARATOR
Intervention: Conventional calcineurin inhibitor (CNI) therapy
Number of subjects: 282
Study 25060610 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN injections of 0.5 mg ranibizumab
Number of subjects: 175
Study 25060610 — intervention group
Group type: COMPARATOR
Intervention: Monthly injections of 0.5 mg ranibizumab
Number of subjects: 175
Study 25060610 — intervention group
Group type: COMPARATOR
Intervention: Non-randomized subjects receiving monthly injections
Number of subjects: 175
Study 22343428 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-week ACT program
Number of subjects: 12
Study 20008055 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-supported care coordination
Number of subjects: 525
Study 20008055 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 525
Study 18324952 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin alone
Number of subjects: 395
Study 18324952 — intervention group
Group type: COMPARATOR
Intervention: Darifenacin + BMP
Number of subjects: 395
Study 16042228 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA) treatment
Number of subjects: 0
Study 16504579 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg/day titrated to 50 mg/day
Number of subjects: 2106
Study 10024335 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 30
Study 10024335 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 30
Study 10024335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Enalapril + Simvastatin)
Number of subjects: 30
Study 7571926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin injected in Tenon's space
Number of subjects: 0
Study 7571926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin injected in retrobulbar space
Number of subjects: 0
Study 7571926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin injected in retrobulbar space and in combination with trental
Number of subjects: 0
Study 7571926 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cerebrolysin)
Number of subjects: 0
Study 10147516 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine strips
Number of subjects: 69
Study 10147516 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole strips
Number of subjects: 69
Study 10147516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline strips
Number of subjects: 69
Study 10147516 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing
Number of subjects: 69
Study 10147516 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined root planing and metronidazole strips
Number of subjects: 69
Study 6162599 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin (BLM) plus radiation
Number of subjects: 157
Study 6162599 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone (Control)
Number of subjects: 157
Study 31955429 — intervention group
Group type: EXPERIMENTAL
Intervention: KE + CHO mix
Number of subjects: 5
Study 31955429 — intervention group
Group type: COMPARATOR
Intervention: CHO (isocaloric CHO equivalent)
Number of subjects: 5
Study 29906741 — intervention group
Group type: EXPERIMENTAL
Intervention: My-GMC (Group medical consultations combined with tablet-based online app)
Number of subjects: 109
Study 29906741 — intervention group
Group type: COMPARATOR
Intervention: Individual medical visit (care as usual)
Number of subjects: 109
Study 29906741 — intervention group
Group type: EXPERIMENTAL
Intervention: My-GMC
Number of subjects: 109
Study 29906741 — intervention group
Group type: COMPARATOR
Intervention: Online app
Number of subjects: 109
Study 27390976 — intervention group
Group type: COMPARATOR
Intervention: Bivalirudin IV bolus of 0.75 mg/kg followed by an infusion of 1.75 mg/kg/h until the end of the PCI.
Number of subjects: 20
Study 27390976 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (70 UI/kg) intravenous bolus.
Number of subjects: 20
Study 24563158 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with direct feedback on 100 cases
Number of subjects: 31
Study 23133602 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha (pegIFNα) 2a with ribavirin for 48 weeks
Number of subjects: 99
Study 23133602 — intervention group
Group type: COMPARATOR
Intervention: pegylated interferon alpha (pegIFNα) 2b with ribavirin for 48 weeks
Number of subjects: 99
Study 20300774 — intervention group
Group type: EXPERIMENTAL
Intervention: Education Group (EG) - standardized multiprofessional psycho-educational program
Number of subjects: 338
Study 20300774 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction Group (IG) - structured training according to national asthma guideline
Number of subjects: 338
Study 20300774 — intervention group
Group type: COMPARATOR
Intervention: Waiting Group (WG)
Number of subjects: 338
Study 17583798 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral insulin 7.5 mg daily
Number of subjects: 372
Study 17583798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 15208057 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% PSS
Number of subjects: 49
Study 15208057 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PSS
Number of subjects: 49
Study 15208057 — intervention group
Group type: EXPERIMENTAL
Intervention: PSS vehicle
Number of subjects: 49